QQQ   282.36 (+0.67%)
AAPL   116.55 (+1.30%)
MSFT   212.25 (+1.03%)
FB   282.70 (+2.02%)
GOOGL   1,592.46 (+0.52%)
AMZN   3,255.00 (+1.50%)
TSLA   425.34 (+1.20%)
NVDA   535.60 (+1.89%)
BABA   316.08 (+3.00%)
CGC   18.90 (+2.00%)
GE   7.19 (-2.57%)
MU   51.89 (-0.48%)
AMD   80.42 (-2.20%)
T   27.03 (-1.28%)
F   7.98 (-0.62%)
ACB   4.21 (-4.32%)
GILD   59.72 (-0.40%)
NFLX   484.92 (-0.68%)
NIO   27.16 (+4.42%)
BA   157.64 (-1.98%)
DIS   123.88 (-0.15%)
QQQ   282.36 (+0.67%)
AAPL   116.55 (+1.30%)
MSFT   212.25 (+1.03%)
FB   282.70 (+2.02%)
GOOGL   1,592.46 (+0.52%)
AMZN   3,255.00 (+1.50%)
TSLA   425.34 (+1.20%)
NVDA   535.60 (+1.89%)
BABA   316.08 (+3.00%)
CGC   18.90 (+2.00%)
GE   7.19 (-2.57%)
MU   51.89 (-0.48%)
AMD   80.42 (-2.20%)
T   27.03 (-1.28%)
F   7.98 (-0.62%)
ACB   4.21 (-4.32%)
GILD   59.72 (-0.40%)
NFLX   484.92 (-0.68%)
NIO   27.16 (+4.42%)
BA   157.64 (-1.98%)
DIS   123.88 (-0.15%)
QQQ   282.36 (+0.67%)
AAPL   116.55 (+1.30%)
MSFT   212.25 (+1.03%)
FB   282.70 (+2.02%)
GOOGL   1,592.46 (+0.52%)
AMZN   3,255.00 (+1.50%)
TSLA   425.34 (+1.20%)
NVDA   535.60 (+1.89%)
BABA   316.08 (+3.00%)
CGC   18.90 (+2.00%)
GE   7.19 (-2.57%)
MU   51.89 (-0.48%)
AMD   80.42 (-2.20%)
T   27.03 (-1.28%)
F   7.98 (-0.62%)
ACB   4.21 (-4.32%)
GILD   59.72 (-0.40%)
NFLX   484.92 (-0.68%)
NIO   27.16 (+4.42%)
BA   157.64 (-1.98%)
DIS   123.88 (-0.15%)
QQQ   282.36 (+0.67%)
AAPL   116.55 (+1.30%)
MSFT   212.25 (+1.03%)
FB   282.70 (+2.02%)
GOOGL   1,592.46 (+0.52%)
AMZN   3,255.00 (+1.50%)
TSLA   425.34 (+1.20%)
NVDA   535.60 (+1.89%)
BABA   316.08 (+3.00%)
CGC   18.90 (+2.00%)
GE   7.19 (-2.57%)
MU   51.89 (-0.48%)
AMD   80.42 (-2.20%)
T   27.03 (-1.28%)
F   7.98 (-0.62%)
ACB   4.21 (-4.32%)
GILD   59.72 (-0.40%)
NFLX   484.92 (-0.68%)
NIO   27.16 (+4.42%)
BA   157.64 (-1.98%)
DIS   123.88 (-0.15%)
Log in
NASDAQ:ADVM

Adverum Biotechnologies Stock Forecast, Price & News

$11.96
+0.08 (+0.67 %)
(As of 10/27/2020 11:25 AM ET)
Add
Compare
Today's Range
$11.85
Now: $11.96
$12.22
50-Day Range
$9.84
MA: $11.52
$12.85
52-Week Range
$6.58
Now: $11.96
$26.98
Volume5,867 shs
Average Volume829,653 shs
Market Capitalization$964.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Read More
Adverum Biotechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323
Employees82

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$2.71 per share

Profitability

Net Income$-64,490,000.00

Miscellaneous

Market Cap$964.69 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$11.96
+0.08 (+0.67 %)
(As of 10/27/2020 11:25 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

How has Adverum Biotechnologies' stock been impacted by COVID-19?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADVM stock has increased by 29.2% and is now trading at $11.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Adverum Biotechnologies?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adverum Biotechnologies
.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Adverum Biotechnologies
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) posted its earnings results on Monday, August, 10th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.06.
View Adverum Biotechnologies' earnings history
.

What price target have analysts set for ADVM?

9 brokers have issued 12 month price objectives for Adverum Biotechnologies' shares. Their forecasts range from $17.00 to $36.00. On average, they anticipate Adverum Biotechnologies' share price to reach $24.38 in the next year. This suggests a possible upside of 103.8% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 12,400,000 shares, an increase of 17.6% from the September 15th total of 10,540,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is currently 9.3 days.
View Adverum Biotechnologies' Short Interest
.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO & Director (Age 56)
  • Mr. Thomas Leung, Chief Financial Officer

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.77%), Candriam Luxembourg S.C.A. (0.38%), Assenagon Asset Management S.A. (0.34%), Pinnacle Associates Ltd. (0.06%), Pacer Advisors Inc. (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Leone D Patterson, Mehdi Gasmi and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies
.

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies
.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Pacer Advisors Inc., Pinnacle Associates Ltd., and Nisa Investment Advisors LLC. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $11.96.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $964.69 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.